Key Market Indicator:
F&G: 23
25.215,70 NASDAQ · 47.521,00 DOW · 6.798,75 S&P · 4.239,07 Gold · 63,49 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
FR0012127173
Filter zurücksetzen
© Globe Newswire
17.11.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
Article
News Preview
OSE Immunotherapeutics annonce que le Comité indépendant d’experts scientifiques (IDMC) recommande la poursuite d’ARTEMIA, l’essai pivot de Phase 3 de Tedo...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
Article
News Preview
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
30.10.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
15.10.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports First Half 2025 Financial Results
Article
News Preview
OSE Immunotherapeutics Reports First Half 2025 Financial Results...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Appointment of Marc Le Bozec as Interim CEO
Article
News Preview
Appointment of Marc Le Bozec as Interim CEO...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
Article
News Preview
Full renewal of the Board of DirectorsElection of Dr. Markus Cappel as Chairman of the Board of Directors...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
Article
News Preview
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025
Article
News Preview
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
Article
News Preview
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
Article
News Preview
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
Article
News Preview
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
12.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Update on Information Relating to the General Meeting of September 30, 2025
Article
News Preview
Update on Information Relating to the General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
Article
News Preview
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025
Article
News Preview
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance Publication of Circular for Combined Annual General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
Article
News Preview
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
Article
News Preview
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
Article
News Preview
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
Article
News Preview
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
Article
News Preview
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General MeetingNew Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi® and Lusvertikimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
Article
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
Article
News Preview
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Half-Year Report on Liquidity Contract with Invest Securities
Article
News Preview
Half-Year Report on Liquidity Contract with Invest Securities...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
Article
News Preview
OSE Immunotherapeutics provides an update on ongoing proceedings...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Publishes Letter to Shareholders
Article
News Preview
OSE Immunotherapeutics Publishes Letter to Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics provides an update on ongoing proceedings
Article
News Preview
OSE Immunotherapeutics provides an update on ongoing proceedings...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
Article
News Preview
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
Article
News Preview
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
Article
News Preview
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
Article
News Preview
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
Article
News Preview
Documents made available to the shareholders for the combined general meeting of June 25th, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
Article
News Preview
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
Article
News Preview
OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
Article
News Preview
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2024
Article
News Preview
Mise à disposition du Document d’Enregistrement Universel incluant le Rapport Financier 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
Article
News Preview
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
Article
News Preview
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Article
News Preview
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.03.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
Article
News Preview
 OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.03.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
Article
News Preview
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
Article
News Preview
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
Article
News Preview
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic ColitisIn Oral Presentation at 20th Congress of ECCO...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.02.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
Article
News Preview
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
Article
News Preview
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO
Article
News Preview
A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral abstracts for 20th Congress of European Crohn’s and Colitis Organization (ECCO) Highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital
Article
News Preview
Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
Article
News Preview
OSE Immunotherapeutics Strengthens Leadership and Executive Committee...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de biotechnologie qui développe des immunothérapies innovantes, en direct ou via des partenariats, pour l’activation et la régulat...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
Article
News Preview
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
Article
News Preview
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral presentations selected for international conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Article
News Preview
al...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
Article
News Preview
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.